|Bid||2.8000 x 36900|
|Ask||2.8000 x 45900|
|Day's Range||2.6500 - 2.8950|
|52 Week Range||2.0900 - 15.8640|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 15, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.98|
Public-private partnership to enable the development of innovative, sustainable infrastructure designed to set the global standard for travel biosecurityBOSTON and NEW YORK, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Ginkgo Bioworks (NYSE: DNA) and XpresSpa Group, Inc. (Nasdaq: XSPA) announced they will continue to support the Centers for Disease Control and Prevention’s (CDC’s) traveler-based SARS-CoV-2 genomic surveillance program through a new contract awarded August 12, 2022. The partnership is expec
Ginkgo is teaming up with Synlogic to launch a new gout drug, moving shares of both stocks higher.
Today we will run through one way of estimating the intrinsic value of Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) by...